Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma

Acta Dermato-Venereologica

Volumn 93, Issue 6, 2013, Pages 663-668

  Kambayashi, Yumi ^a   Fujimura, Taku ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cd163+ M2 macrophages; Foxp3; IL 27; Keratoacanthoma; MMP 9; pSTAT1; Regulatory T cells; Squamous cell carcinoma

Indexed keywords

CD3 ANTIGEN; GELATINASE B; INTERLEUKIN 27; STAT1 PROTEIN;

ARTICLE; CANCER CELL; CD163+ MACROPHAGE; CD3+ FOXP3+ TREG; CELL COMPARTMENTALIZATION; CELL COUNT; CELL POPULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTERLEUKIN 27 PRODUCING CELL; KERATOACANTHOMA; LYMPHOCYTE FUNCTION; MMP 9+ CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKINS; KERATOACANTHOMA; MACROPHAGES; MATRIX METALLOPROTEINASE 9; NEOPLASMS, SQUAMOUS CELL; PHOSPHORYLATION; RECEPTORS, CELL SURFACE; SKIN; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84886423290     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1597     Document Type: Article

References (37)

1. Elder DE, Elemenitsas R, Johnson BL Jr, Murphy GF. Lever's histopathology of the skin, 10th edn. Philadelphia: Lippincott-Raven, 2008.
2. Clausen OP, Beigi M, Bolund L, Kølvraa S, Gjersvik PJ, Mørk G, de Angelis PM. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002; 119: 1367-1372.
3. Clausen OP, Aass HC, Beigi M, Purdie KJ, Proby CM, Brown VL, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126: 2308-2315.
4. Li J, Wang K, Gao F, Jensen TD, Li ST, DeAngelis PM, et al. Array comparative genomic hybridization of keratoacanthomas and squamous cell carcinomas: different patterns of genetic aberrations suggest two distinct entities. J Invest Dermatol 2012; 132: 2060-2066.
5. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110: 2983-2990.
6. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-352.
7. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
8. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
9. Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 expression CD4+CD25 high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immmunol 2004; 173: 1444-1453.
10. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 2010; 59: 1-6.
11. Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M, Pierson KC, Pitts-Kiefer A, Fan L, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011; 131: 1322-1330.
12. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 2011; 129: 1016-1025.
13. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-2231.
14. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19: 641-644.
15. Shibata S, Tada Y, Kanda N, Nashiro K, Kamata M, Karakawa M, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 2010; 130: 1034-1039.
16. Adamson AS, Collins K, Laurence A, O'Shea JJ. The Current STATus of lymphocyte signaling: new roles for old players. Curr Opin Immunol 2009; 21: 161-166.
17. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
18. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Res 2012, 14: R16.
19. Fujimura T, Okuyama R, Ito Y, Aiba S. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008; 158: 1256-1263.
20. Fujimura T, Kambayashi Y, Hidaka T, Hashimoto A, Haga T, Aiba S. Comparison of Foxp3+ regulatory T cells and CD163+ macrophages in invasive and non-invasive extramammary Paget's disease. Acta Derm Venereol 2012; 92: 625-628.
21. Tojo G, Fujimura T, Kambayashi Y, Aiba S. Systemic lupus erythematosus accompanied with psoriasis induces IL-27 producing cells in both affected skin. Case Rep Dermatol 2012; 4: 180-185.
22. Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165: 990-996.
23. Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogeneic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 2007; 46: 159-167.
24. André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Surveillance of antigen-presenting cells by CD4+CD25+ regulatory T cells in autoimmunity. Am J Pathol 2009; 174: 1575-1587.
25. Mahnke K, Ring S, Johnson TS, Schallenberg S, Schönfeld K, Storn V, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur J Immunol 2007; 37: 2117-2126.
26. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells (Treg) stimulate B7-H1 expression in myeloid derived suppressor cells (MDSC) in ret melanomas. J Invest Dermatol 2012; 132: 1239-1246.
27. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
28. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-790.
29. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
30. Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010; 20: 318-325.
31. Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006; 25: 7260-7266.
32. Monhian N, Jewett BS, Baker SR, Varani J. Matrix metalloproteinase expression in normal skin associated with basal cell carcinoma and in distal skin from the same patients. Arch Facial Plast Surg 2005; 7: 238-243.
33. Rasheed H, Tolba Fawzi MM, Abdel-Halim MR, Eissa AM, Mohammed Salem N, Mahfouz S. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides. Am J Dermatopathol 2010; 32: 1629.
34. Ishibashi M, Fujimura T, Hashimoto A, Haga T, Onami K, Tsukada A, Kambayashi Y, et al. Successful treatment of MMP9-expressing angiosarcoma with low-dose docetaxel and biphosphonate. Case Rep Dermatol 2012; 4: 5-9.
35. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67: 11438-11446.
36. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170: 4886-4890.
37. Sugiyama N, Nakashima H, Yoshimura T, Sadanaga A, Shimizu S, Masutani K, et al. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1). Ann Rheum Dis 2008; 67: 1461-1467.